China Rituximab Market Investigation Report 2018 Forecasts The International News Magazine Rituximab (trade names “MabThera” by Roche, “Rituxan” by Genetech) is a chimeric monoclonal antibody against the protein CD20 approved in 1997 to treat tumor. It is very effective and shows good tolerance in the treatment of Bcell lymphoma. As people ... |
